hotspot -WSS

hotspot

author：entertainment 2025-08-26 07:42:29 - browse：1

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

focus

WSS

A public health expert passes on football's full body collisions for youths

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Just how do doctors, lawmakers, and the public define abortion?

Bispecific antibodies are next new thing in cancer immunotherapy

A public health expert passes on football's full body collisions for youths

focus

hotspot

entertainment

What does generative AI mean for health care? We asked experts

Biden administration plans revamp of organ transplant system

Alkermes shareholders re

Bispecific antibodies are next new thing in cancer immunotherapy

Jerome Adams on the need for new antivirals for Covid

Sen. Paul opposes bill to ban Chinese biotechs

Trump demands the U.S. pay no more for drugs than other countries … again

UnitedHealth quietly bought dozens of outpatient centers

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Wikipedia

Amylyx ALS drug failure raises questions and concerns

Reanimated hearts work just as well for transplants, study finds

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Change Healthcare cyberattack prompts Medicare loan program

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

The problem with charging patients to message their doctors

Wikipedia

explore

focus

knowledge